Fintel reports that on February 11, 2025, Raymond James downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform.Maximize Your Portfolio with Data Driven Insights:Leverage ...

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 ...

American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to le ...

Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

Anavex Life Sciences Corp (AVXL) is expected to report $-0.17 for 1Q. BankFinancial Corp (BFIN) is expected to report $0.20 for 4Q. Barrick Gold Corp (ABX.T,GOLD) is expected to report $0.63 for 4Q.

Nusrat Fateh Ali Khan—Trad Album” was all it said on the cover. “I was always browsing, and I would spend a lot of afternoons after lunch there,” Mullan says. “I knew that would be the ultimate find—a ...

Lipella Pharmaceuticals LIPO stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. IN8bio INAB shares increased by ...